Steffan Joe's Album: Wall Photos

Photo 8 of 8 in Wall Photos

Live Biotherapeutic
Products and Microbiome Contract Manufacturing Market by Roots Analysis

over 85 microbiome-based, live biotherapeutic products under preclinical and
clinical development, the demand for R&D and manufacturing services for such
products is anticipated to increase beyond the capabilities of innovator
companies alone


Roots Analysis has announced the
addition of “Live Biotherapeutic Products and Microbiome Contract
Manufacturing Market, 2020-2030: Focus on Active
Pharmaceutical Ingredients and Finished Dosage Forms, 2020-2030” report to its
list of offerings.

Manufacturing live
biotherapeutic products is both technically challenging and financially
demanding; as a result, innovator firms are becoming increasingly reliant on
contract service providers to access specialized facilities and optimize
overall costs.

order this 300+ page report, which features 140+ figures and 125+ tables,
please visit this -

Key Market Insights

Over 25 players claim
to provide microbiome-based live biotherapeutics contract manufacturing

More than 80% of the companies
engaged in this domain are mid-sized and large firms; examples of firms established in 2019 include Arranta Bio and BacThera
(a Lonza and Chr. Hansen joint venture). Further, nearly 50% of the CMOs
have established the necessary expertise for handling both anaerobic and
aerobic strains.

35+ manufacturing facilities
focused on live biotherapeutics have been established worldwide

Majority (~55%) of the
manufacturing facilities are located in Europe, followed by North America. Prominent manufacturing hubs
in the Europe include (in decreasing order of number of manufacturing
facilities) the UK,
France, the Netherlands, Italy, Germany, Switzerland, and Sweden.

Approximately 88% of the
total installed capacity is dedicated to commercial scale manufacturing

Whereas, rest (~10%) of the capacity is being used for preclinical / clinical
scale manufacturing of microbiome products. In addition, over 60% of the total
current global, installed manufacturing capacity is installed in Europe.

Over 170 registered
clinical trials involved the use of microbiome-based live biotherapeutics

Majority of these studies are
being conducted at various hospitals / centers across the US. Examples of
leading non-industry players include (in decreasing order of number of
trials) University of California, National Institute of Allergy and
Infectious Diseases, Radboud University, and The University of Texas Health
Science Center.

The global clinical demand
for microbiome-based live biotherapeutic products is anticipated to grow at a CAGR of 23%,
between 2020 and 2030

By 2030, over 31,000 patients
are estimated to be enrolled in the clinical trials involving the use of
microbiome-based live biotherapeutics. Industry players are anticipated to
contribute majority (over 60%) of the demand in the short-term as well as

Several big pharma players are
actively engaged in the microbiome live biotherapeutics domain

In fact, leading
pharmaceutical companies have partnered with smaller business entities to
develop manufacturing capabilities related to microbiome-based therapies /
diagnostics. Examples of such small ventures with players with in-house
capability include (in alphabetical order) Assembly Biosciences,
Enterome Bioscience, Finch Therapeutics and NuBiyota.

By 2030, North America and Europe are anticipated to
capture over 85% of the market opportunity

terms of type of product manufactured, APIs currently represent the highest
share (58%); this trend is unlikely to change in the foreseen future.

To request a sample
copy / brochure of this report, please visit this -

The USD 300 million (by 2030) financial opportunity
within the microbiome contract manufacturing market has been analysed across
the following segments:

§ Type
of Product Manufactured

§ Active
Pharmaceutical Ingredients (APIs)

§ Finish
Drug Formulations (FDFs)

§ Type
of Type of Formulation

§ Solid

§ Oral

§ Injectables

§ Others

§ Scale
of Operation

§ Clinical

§ Commercial

§ Company

§ Small-sized

§ Mid-sized

§ Large

§ Key
Geographical Regions

§ North

§ Europe

§ Asia-Pacific
and Rest of the World

The report features
inputs from eminent industry stakeholders, according to whom the microbiome
therapeutics contract manufacturing services market is likely to witness
substantial growth in the foreseen future. The report includes detailed
transcripts of discussions held with the following experts:

The research covers
detailed profiles brief profiles of several companies (including those
listed below); each profile features an overview of the company, its
financial information (if available),
microbiome-related service portfolio, facilities dedicated to microbiome
manufacturing, and an informed future outlook.

§ Biose®


§ Capsugel
(acquired by Lonza)

§ Cerbios-Pharma

§ Cobra
Biologics (acquired Cognate Bioservices)

§ Inpac

Paragon Bioservices (a unit of Catalent Biologics)


For additional
details, please visit or

You may also be
interested in the following titles:

HPAPI and Cytotoxic Drugs Manufacturing Market (3rd Edition), 2020-2030

Antibody Contract Manufacturing Market, 2020 – 2030

The Human Microbiome Market: Focus on Therapeutics (including gut-brain axis targeting
drugs), Diagnostics and Fecal Microbiota Therapies (3rd Edition), 2019-2030

About Roots Analysis

Roots Analysis is one of the fastest growing
market research companies, sharing fresh and independent perspectives in the
bio-pharmaceutical industry. The in-depth research, analysis and insights are
driven by an experienced leadership team which has gained many years of
significant experience in this sector. If you’d like help with your growing
business needs, get in touch at

Contact Information

Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

Facebook -

LinkedIn -

Twitter -